Register for free to
view the full innovation profile.
It offers a test for relapse with power comparable to others on the market at a fraction of the cost.
About
Description: Novel accelerated progression relapse test can separate patients with good prognosis from those with bad prognosis using an assay of four identified genes at a fraction of the cost of other methods. Many breast cancer patients will remain relapse-free even without chemotherapy; however, accepted clinic-pathological variables are unreliable indicators of prognosis. The novel accelerated progression relapse test separates patient with good prognosis from those with a poor prognosis using a simple assay of four genes. It offers a test for relapse with power comparable to others on the market at a fraction of the cost.